Historically, sample management successfully focused on providing compound quality and tracking distribution within a diverse geographic. However, if a competitive advantage is to be delivered in a changing environment of outsourcing, efficiency and customer service must now improve or face reconstruction. The authors have used discrete event simulation to model the compound process from chemistry to assay and applied lean manufacturing techniques to analyze and improve these processes. In doing so, they identified a value-adding process time of just 11 min within a procedure that took days. Modeling also allowed the analysis of equipment and human resources necessary to complete the expected demand in an acceptable cycle time. Layout and location of sample management and screening departments are key in allowing process integration, creating rapid flow of work, and delivering these efficiencies. Following this analysis and minor process changes, the authors have demonstrated for 2 programs that solid compounds can be converted to assay-ready plates in less than 4 h. In addition, it is now possible to deliver assay data from these compounds within the same working day, allowing chemistry teams more flexibility and more time to execute the next chemistry round. Additional application of lean manufacturing principles has the potential to further decrease cycle times while using fewer resources. (Journal of Biomolecular Screening. 2009:515-522) 
INTRODUCTION
T he pharmaceutical industry is currently facing significant challenges, with diminishing pipelines of new drugs and a failure to replenish the pipeline. 1 It is therefore critical that the pharmaceutical industry enhance productivity and reduce the cycle time of drug discovery. There is no magic bullet to tackle the current drop in drug discovery productivity within the pharmaceutical industry; all stages of the drug discovery process need to be enhanced. In this article, we look at targeting just 1 small step in this process: the speed at which compounds are transferred from chemistry teams to primary assays, as an example of how the application of lean techniques can improve the performance of drug discovery processes. As processes have been centralized and automated (to enhance throughput), we found that this task, which used to be accomplished simply and quickly in old small-scale, low-throughput laboratories, was now generally taking 2 days to run through the high-throughput processes. We looked to lean techniques to combine the required high throughput of the modern laboratories with the rapid cycle times achieved in the old low-throughput laboratories.
Lean management has its origins at Toyota and was pioneered by Taiichi Ohno. The potential to apply these principles more widely was highlighted by Womak and Jones, 2 who described 5 essential steps in applying lean techniques: 1) Specify value in the eyes of the customer, 2) identify the steps in the process and eliminate those that do not directly add value, 3) tightly link the value-adding steps so that a flow is achieved at the pull of the customer, 4) involve and empower employees, and 5) continuously improve in pursuit of perfection.
In recent years, lean principles have been incorporated into Six Sigma methodology. Six Sigma was developed to control and improve manufacturing quality at Motorola in the early 1980s. Six Sigma gained much wider acceptance as a general quality improvement and problem-solving tool after Jack Welch applied the techniques to improve and transform all parts of the General Electric business in the 1990s. 3 Six Sigma provides a structure framework into which lean improvement programs can easily fit. This combined approach has become known as Lean Six Sigma.
A potential disadvantage of traditional lean implementation is that process improvement is generally performed by experimentation with the real process in a series of "Kaizen" events.
This may be resource intensive and can be stressful for those involved. To increase the chance of success, reduce resource requirements, and make the improvement process more predictable and less stressful, we have turned to process simulation to build, and then subsequently experiment on, a virtual model of the laboratory prior to implementation on the laboratory floor.
An important lesson we have learned is that lean processes must be supported by lean layouts; distances that may appear insignificant when moving one large batch of work around between process steps can become a real problem when that batch is divided up and each small unit must be moved the same distance (dividing a batch in 2 will double the total distance moved); without lean layouts, movement can increase very significantly with reduced batch sizing, and it is critical to co-locate process steps to move small batches through a process rapidly and efficiently.
Historically, GlaxoSmithKline has used lean design in a range of laboratory environments. This is both a result of experience and the application of lean principals over the past 5 years; for example, within GlaxoSmithKline, we aim to co-locate both chemistry and screening teams such that compound transit times are minimal. New programs have assays generated at or transferred to their local site where possible. In addition, previous projects had seen the creation of the Discovery Research Automation Facility buildings at Harlow and Upper Providence, where the concept of co-locating screening, chemistry, and sample management operations in a factory-like environment was explored. Screening and sample management operations at Harlow have further embraced workcell systems from lean manufacturing, whereby the location of all required equipment for designated tasks within a process flow is precisely placed within a small area to build an efficient production line. Co-location of the individual elements (workcells) then minimizes handover points and further stimulates flow within a process. Having these systems already in place has facilitated the process developments described here.
In this article, we illustrate a Lean Six Sigma program aimed at reducing the latency of compounds in transit between chemistry and biology teams. This project has been part of a wider implementation of lean techniques, such as the reduction of batch sizing and increase in frequency of key biological assays.
METHODS AND RESULTS

Overall improvement structure
The improvement process employed was based on the Six Sigma DMAIC technique, in which a project is broken down into 5 phases: define the goals of the project, measure the current process, analyze the current process to identify areas for improvement, improve the process, and control the new process to embed it.
As this project was aimed at reducing cycle times, the lean technique of value stream mapping 4 formed the basis of our analysis, and this enabled process simulations to be generated, allowing further analysis and testing of suggested improvements before implementation in the laboratory.
Defining the goals (define)
The improvement process began by defining the goal. The initial aim was to reduce the required latency time of compounds within sample management for compounds being processed for structure activity relationship (SAR) screening. This was to be done with minimal investment. An important part of this stage was also to define the boundaries of the project: The project was to start with compounds received from chemists and was to finish with assay plates available to the SAR screening laboratory. We selected 2 programs to pilot alterations to this process, and the data from this pilot are reported within this article. The goal would be further refined as the measure and analysis phases allowed a more quantitative definition: The goal was refined to the following: to reduce the required latency period in sample management from 2 days to 4 h.
Current state mapping (measure, analyze)
Measurements were based on the value stream mapping technique. Compounds sent from chemists were tracked through the process. At each process step, the required resource was noted along with process times broken down into changeover time (the fixed time required before the 1st compound can be processed through a step, e.g., equipment setup, preparation of the work area) and cycle time (the time required for each unit of work processed; the unit may be a compound or a plate of compounds depending on the stage of the process). Process step length may then be modeled based on these parameters. An estimate of the variation is also made (which is used in the simulation modeling): We have found that physical processes within a sample management laboratory tend to have moderate variation (30%-70% coefficient of variation around predicted mean time, data not shown).
The key process steps are shown as a value stream map in Figure 1 . The process steps are described below.
Process step 1: weighing. After delivery of compound, the process starts with registration and weighing of the compounds. This step takes ∼28% of the raw total process time but consumes ∼50% of the total full-time equivalent (FTE) time in the process because of the manual nature of compound weighing. The weighed compounds are loaded into a temporary solid store.
Process step 2: dissolving. Compounds are retrieved from the temporary solid store and dissolved in DMSO using a Tecan Genesis liquid handler (RSP200; Tecan UK Ltd). The dissolved compound is then transferred to 2-dimensional barcoded plastic tubes. These are loaded into a solution tube store and stored at 4 °C. This step takes ∼27% of the raw total process time and consumes ∼23% of the total FTE time in the process. There is a once-daily dispatch of compounds from the tube store for compound quality control (QC); this is frequently performed at night. Compounds cannot be sent for SAR screening until they have been dispatched for QC (although QC data are not available until after the compounds have been dispatched for SAR screening).
Process step 3: creation of a mother plate. Tubes are picked from the solution tube store and defrosted. Liquid is then transferred from the tube into a microplate (Tecan Genesis Liquid Handler, RSP200, Tecan UK Ltd). Tubes are then reloaded into the store. This step takes ∼17% of the raw total process time and consumes ∼6% of the total FTE time in the process.
Process step 4: creation of assay plates. The mother microplate has a serial dilution performed (Biomek FX) to give 11 concentrations of each compound. Assay plates are then bar coded, and the compound is transferred to assay plates (Biomek FX or Labcyte Echo). Controls may be added to these plates. This step takes ∼28% of the raw total process time and consumes ∼21% of the total FTE time in the process.
Scheduling
Process steps 1 and 2 are combined on 1 day. The QC dispense may be made overnight and process steps 3 and 4 performed the following day. The plates are considered available for assays by the end of day 2 (or by the beginning of day 3).
Process cycle efficiency
The process cycle efficiency is calculated in equation 1, in which the raw process time in sample management is 2 h 30 min for a typical job (20 compounds from 1 program routed to 4 assays, n = 2). The scheduled lead time (overall cycle time) is 48 h.
Raw process cycle efficiency = raw process time/ overall cycle time = 2.5/48 = 5%.
A significant proportion of the raw process time is nonvalue adding (e.g., compounds are waiting while other compounds in the batch are being processed, compound is transferred into 2 intermediate containers and 1 intermediate plate before transfer to the assay plate, the compounds are transferred 3 times into and out of stores during the process, and the compound is frozen and thawed during the process).
The value-adding time (the time an essential physical process is occurring) for a single compound to a single assay is as follows and adds up to 11 min (0.18 h) per compound: weigh: 1.9 min; dissolve and sonicate: 0.5 min; serial dilute: 8 min; and transfer to plate: 0.5 min.
Value-adding cycle efficiency = value-adding time/ overall cycle time = 0.18/48 = 0.4%.
Therefore, without changing any raw process steps, cycle time could be compacted to 5% of the current value, and theoretically (if only the value-adding steps were performed), cycle time could be compressed to 0.4% of the current value as calculated in equation 2.
Both lean and Six Sigma philosophies highlight the importance of first maximizing current process efficiency before considering capital investment to improve raw process times. After analysis of the current state value map, it was decided to set a target of compressing cycle time to 4 h (approximately 10% of the original cycle time); this target was set to allow a buffer time approximately equal to the raw processing time. Figure 1 shows the value stream map points. It was thought major improvements may be made at several points: Samples could by preweighed by chemists wishing to send samples for rapid processing. Storage of solids in the temporary solid store could be removed, with samples moving directly from weighing to dissolution. The QC dispatch could be removed from the critical path so that tubes could be dispatched directly to assays without having to wait for the overnight QC dispatch (the dispatch has no effect on dispatch of compounds to assay as QC data are not available before dispatch to assays is made). A reduced safety buffer could be instigated, reducing the time allowed to ensure that compound plates are ready for the assay, and the schedule would be amended to reflect the changes being made.
Future state mapping, simulation, and implementation (improve)
In value stream mapping, the desired new process is known as a "future state map." The modified planned process is described in Figure 1b . A target time of 4 h was set to allow processing of compounds in half a day for an assay the next half day.
Prior to implementation, a virtual model of the laboratory was built using Simul8 discrete event simulation software (www .simul8.com). 5 This laboratory model contains virtual models of each piece of equipment in the lab and the human resources available (including patterns of availability throughout the working day), and it has work arriving based on the current workload of the lab (including the normal variability seen in work between days). As work flows through the virtual model, resources are used in a manner that closely resembles real life (e.g., equipment may need a manual setup and then a walk-away process time that is dependent on the size of the particular job being processed). The model allows detailed analysis of the speed of work flow through the lab and utilization levels of each piece of equipment or human resource. The model may then be altered and experimented upon to allow "what if?" scenarios to be played out in the virtual lab before implementation in the real lab.
The model predicts that the system can achieve approximately 85% of jobs within the target cycle time of 4 h, although >98% are achieved within 6 h ( Fig. 2a) at approximate current FTE levels (approximately 12 FTE work in this system currently). The average cycle time was about 3 h (Fig. 2b) . The modeled cycle time is therefore longer than the value stream map suggests. This is a common finding (when comparing simulation results to raw process times) as the simulation model takes into account variable workloads and conflicts of resources between jobs. The value stream map method is ideal for being a central tool to understand the current process and where very significant improvements can be made, but we have found that simulation provides a more realistic view of expected performance in laboratories where workload is variable and jobs may be frequently competing for the same resources (equipment or people).
The simulation model highlighted the risk that not every job will complete within 4 h of arrival and that some will take longer. This can be due to workflow peaks on certain days, although in a smoothed workflow model controlled by scheduling, this should have minimal effect; in our case, it is more significantly affected by the individual program/dispense requirements. A program that regularly submits 1 plate of compounds (or less) that requires screening in just a single assay is, for obvious reasons, much easier to produce in 4 h than a dispense that pulls hundreds of compounds from multiple programs and requires screening in 10s of assays. In the latter case, it can take longer than the 4-h time period to replicate the plates, especially if low-volume acoustic dispense is required. However, an express-like service can be created by practical steps, for example, scheduling some assays to run with a 6-h cycle time in sample management or using robotic systems that allow late submission of compounds on day 1 but produce plates over night.
The simulation model has also been used to investigate the impact of changing workloads (Fig. 3) . The system has the capacity to cope with twice the average daily amount of work 
FIG. 3.
Results from the simulation model showing system performance at current full-time equivalent (FTE) levels (12 FTE) at changing throughput (expressed as a fraction of current throughput). Graph shows proportion of immediate processing jobs achieving a target cycle time (from compound arrival through assay plate preparation) of (and an assessment of workload patterns revealed that peak days in the real process were twice the daily average). The ability to meet the target cycle times decreases as throughput increases (if no extra capacity is added to the system), so if a significant (>20%) increase in throughput is expected, then either target cycle times need to be relaxed or extra capacity needs to be added to the system. This is in line with mathematical models of throughput and cycle time, in which cycle time increases nonlinearly with resource utilization. 6 The simulation model was also used to predict the outcome of a limited trial of the process in which only a small subsection of projects were moved through the proposed new process (this reduces the potential for conflicts of work and would be expected to have a reduced cycle time). The model of a trial system predicted an average cycle time of 2 h 28 min (SD = 0.8 h); this would later be used to help validate the simulation model against findings in the lab.
IMPLEMENTATION
Two programs were chosen to pilot the new process. The schedule for these programs was adjusted to take into account the new process, as shown in Figure 4 . The chosen pilot programs had several key attributes: 1) The program team was comfortable with testing a new process, 2) the programs were from 2 different sites in the United Kingdom, and 3) programs were chosen that had recently entered lead optimization and hence where rapid SAR would be expected to positively affect overall program cycle time (i.e., where SAR was key to driving decisions).
Removal of known blockers
Analysis of our systems had identified one obvious block on moving samples through our system in less than 24 h. Historically, the compound quality assessment (QA) required the generation of a single plate containing all samples that had entered the solution tube store since the last time the QA plate had been produced (typically 24 h). Value stream mapping identified that this step was not on the critical path for plate creation and could therefore be moved out of the plate creation process. However, critically, the code within the software controlling this process stated that the QA plating must be the 1st dispense from any new tube. The rationale here was that QA used to demonstrate that the sample is pure and correct is critical to understanding any screening data; in a system that allowed 2 days to process samples through sample management, this was acceptable (QA data were not returned sufficiently fast enough to prevent dispensing of poor-quality samples but were available to highlight assay data that came from poor samples). Before we could investigate how quickly we could move samples through this system, this block had to be removed yet retain the importance of the QA plating. Hence, the code was altered to allow just 1 dispense before the QA dispense, allowing an express immediate processing request to be fulfilled, which supplied critical screening data, while maintaining an assurance that the QA dispense will be fulfilled in a time-relevant manner. Any sample that was present in the solution tube store at the time of a QA dispense would still be added to the QA plate as normal, only samples that use the express service arriving in the store the same day as dispense would not have QA prior to the assay being run. These samples would be added to the next QA plate, data from which should be available within 24 h. This means that chemistry decisions could be made without the appropriate QA. However, this is possible only for a small number of compounds, and with more than 90% of new compounds passing the identity and purity QA, this is further reduced. To ensure any issues are captured, 2 safety nets are also in place: First, there is a tool that allows chemistry teams to adjust potencies outside of the corporate data tables based on the concentration data, and second, the sample management team responsible for this alerts chemistry teams of any samples that fail QA such that the appropriate decision making can be reviewed.
First experiences
Our 1st attempt to pass samples through the process revealed some unforeseen practical issues; although we could pass samples physically through the process very quickly, we could not pass the electronic sample at the same rate (the rate of electronic transfer had slowed since timings were captured for the process simulation). This was largely due to data transfer when the samples were passed via the temporary solid store. This had, however, been highlighted within the modeling analysis as a potential part of our process that could be removed without losing value in our product. Hence, to resolve this problem, we enlisted a legacy system that bypassed the temporary solid store. However, this system required that data about the samples be submitted and required that the samples be preweighed by the submitting chemist. In addition, the samples would need to be segregated from other program compounds; a rather lowtech solution to this was to have the samples submitted in sealed plastic bags with the program code written on them so they traveled to the lead optimization team together and were easily identifiable. When this system was trialed, we had some success, although compliance with data provision was an issue: We found that we often received a sample physically but had no electronic data to process it. By the time this was provided, it was often too late to get these samples onto the plate. Again, a simple IT solution enabled an inventory search that allowed us to extract the data we required, and it also provided a check to see if samples had been submitted to sample management but not yet delivered to the lead optimization team. When this occurred, we now had an early warning system and could ensure that all submitted samples were included.
This system was run on 4 live occasions successfully delivering plates to the assays on time (average 1 h 38 min, n = 4). The trial was approached in a dynamic manner, taking learning and improving the process at each step to make the process more efficient. During this phase, we made several observations/ changes within the process.
Having made these changes and demonstrated that the modeling was a realistic projection of our system, we now had sufficient confidence to merge all compounds onto the express plate for these programs. This was now done by using 1 dispense and generating just 1 plate per week for each program.
Trial data
Over the next 2 mo, the immediate processing trial evolved a process that could take solid compounds, generate assayready plates, screen these compounds, and post data within the same day (Fig. 5) . This trial has demonstrated a solid to assayready plate cycle time of 2 h 19 min (SD = 0.44 h, n = 10), confirming the predictions of the simulation model. In common with many cycle time measurements, the data are right skewed (skewness = 1.4) as there is no opportunity to be shorter than the minimum processing time but there are plenty of opportunities for significant delay beyond the minimum process time.
Having demonstrated that the assay plates could be created within a 4-h time frame, we developed our experiment beyond the initial goals. The extension now included running of the assays and data publishing. This completed the new process deployment, as shown in Figure 4 . Using program A, we demonstrated a solid to data cycle time of 7 h 38 min (SD = 1.31 h, n = 8) and for program B a cycle time of 24 h 0 min (SD = 7.07, n = 8), with the range in this case being 7 to 25 h. These short cycle times are facilitated by the physical location of both sample management and screening groups, and clear communication between teams is key at handover points. During the trial, several minor issues occurred but did not disrupt our ability to deliver this service.
Benefits and cost to drug discovery
The projected advantages for this service over a standard service that takes 2 days are that this service should shorten program cycle times (and is especially powerful when combined with increased frequency, another arm of the lean approach being taken to compound profiling). That compound master and daughter plates are not frozen between dispense and use reduces the risk of precipitation and degradation, and there should be an increased opportunity to retest compounds before the next submission cutoff, reducing the effect of assay failures.
However, there are also anticipated disadvantages. There is an increased risk of compound/data delivery being disrupted by unforeseen events. Within our system, we know minor events are tolerated within trial capacity, but more serious issues increase the risk of service disruption. Although during the trial there was no material cost to the provision of this service, for this to be used more widely, it is imperative that sample management maintain a surplus capacity such that cycle times can be kept low. In addition, different weighing equipment and methods exist within chemistry and specialist sample management laboratories; hence, variability could be introduced into this system. We view this as a minimal risk as the likely variance introduced from weighing using different equipment is very small when compared with the whole assay system variance, and as in any new sample, processing at GlaxoSmithKline QA is able to control for purity and concentration should significant issues arise. The potential disadvantages must be managed at a program level; hence, frequent open communication is key to the continued success of these initiatives. For example, sample management must explain the potential for samples to not reach an assay, and the program team must make a cost-benefit analysis to see if this is acceptable. Programs that have easily rerun assays with low reagent generation burden will no doubt be happy to take these risks; however, programs that have just a once-weekly cycle of primary culture reagent-based assays would rather have compounds regularly queued than waste valuable resource in the assay. It is also important to consider that assays/program requirements change over the lifetime of a program, and at different time points, the requirement for an express service is also likely to change. Programs drawing hundreds of compounds from pharmacophor analysis of initial high-throughput screening hits may be less interested than later-stage lead optimization programs, in which iterative chemistry data are key to making the next advance.
Control
Since running the trial described above, the 2 programs reported have continued to use the service, and plates have never failed to make the assay slots. We hope to expand the availability of this service to all programs, as modeling suggests that this can be accommodated by a process that has morning and afternoon compound-handling slots that provide assay-ready plates for midday and for the start of the next day, respectively. In addition, we hope to further streamline and enhance our IT both by adding new functionality, such as the ability to weigh compounds within sample management for the express service, and by improving the speed of the data transfer infrastructure, such that there is little risk of this being the bottleneck in an express service.
CONCLUSIONS
We have used standard Lean Six Sigma techniques (based on value stream mapping in a DMAIC project structure) to very significantly reduce the cycle time of a high-throughput sample management laboratory processing compounds from chemists into 2 routine primary assays. In addition, we now plan to further expand this to a total of 40 express dispense slots across 3 GlaxoSmithKline sites. Minimal investment was required to achieve these benefits, and the new process eliminated unnecessary steps and was much more efficient. Process simulation allowed testing of the process in silico before implementation and enabled experimentation of scenarios that are difficult to simulate in the laboratory (e.g., changing workloads).
